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Öz
Amaç: Amacımız transrektal ultrason (TRUS) kılavuzluğunda yapılan 
prostat biyopsisinde (PB) uygulanan periprostatik sinir blokajında (PPSB) 
prostat hacmi başına en uygun prilokain dozunun hesaplanmasıdır.
Gereç ve Yöntem: 2011-2013 yılları arasında 12 kor TRUS kılavuzluğunda 
PB alınan 83 hastanın tıbbi kayıtları geriye dönük incelendi. Prostat boyutu, 
aksiyel planda antero-posterior (Boyut 1) ve transvers ölçüm (Boyut 2) ve 
sagittal planda kraniyo-kaudal ölçüm (Boyut 3) kullanılarak hesaplandı. 
TRUS-PB esnasındaki visual analog skala (VAS), prostat hacimleri ve 1 ml 
prostat hacmi başına uygulanan prilokain dozu değerlendirildi. Hastaların 
VAS ile prostat hacimleri, prostat boyutları ve uygulanan prilokain dozları 
arasındaki korelasyon Cubic regresyon testi ile hesaplandı.
Bulgular: VAS ile prostat boyut 1, 2, 3 ve prostat hacmi arasında anlamlı 
olarak pozitif korelasyon mevcuttur (p<0,05). Ancak VAS ile 1 ml prostat 
hacmi başına prilokain dozu arasında anlamlı olarak negatif korelasyon 
mevcuttur (r=-0,402, p<0,01). Kübik regresyon formülüne göre TRUS 
kılavuzluğunda PB sırasında hafif ve rahatsız etmeyen ağrı düzeyi (VAS<2) 
için PPSB sırasında yapılması gereken maksimum prilokain dozu 1 ml 
prostat hacmi başına 0,1 ml prilokain infiltrasyonudur.
Sonuç: TRUS kılavuzluğunda PB sırasında saptanan VAS, prilokain dozu, 
prostat hacmi ve özellikle antero-prosterior ve kraniyo-kaudal prostat 
boyutlarından anlamlı olarak etkilenmektedir. TURS kılavuzluğunda PB 
esnasındaki ağrı 1 ml prostat dokusu başına 0,1 ml prilokain dozu ile etkin 
olarak kontrol edilebilmektedir.
Anahtar Kelimeler: Ağrı, prilokain, prostat, periprostatik sinir blokajı, 
transrektal ultrason
Summary
Objective: We aimed to calculate the optimum dose of prilocaine per one 
mL prostate volume in periprostatic nerve block (PPNB) during transrectal 
ultrasound (TRUS) guided prostate biopsy (PBx).
Materials and Methods: We retrospectively evaluated the medical records 
of 83 patients from whom 12 cores TRUS guided PBx were obtained 
between years 2011 and 2013. Prostatic sizes were evaluated separately 
as Size 1 (anterior-posterior on the axial plane), Size 2 (transversal), and 
Size 3 (cranial-caudal on the sagittal plane) for all patients. The visual 
analog scores (VAS) of the patients during PBx, prostatic volumes, and 
prilocaine doses per one mL prostate were evaluated. The correlation 
between VAS of patients during PBx and prostatic volume, the prostatic 
sizes and prilocaine dosage per one mL prostate was analyzed using Cubic 
regression test.
Results: It was found that VAS scores of patients were significantly positive 
correlated with prostatic volume, Size 1, 2 and 3 (p<0.05). However, 
there was a negative significant correlation between VAS and prilocaine 
dose per one mL prostate volume (r=-0.402, p<0.01). The dose of 0.1 
mL prilocaine infiltration per one mL prostatic tissue in PPNB was the 
maximum dose that caused a mild and under annoying pain (VAS<2) in 
patients according to cubic regression formula.
Conclusion: Prilocaine dosage, prostatic volume and prostatic sizes 
(especially anterior-posterior and cranial-caudal) significantly affect VAS 
scores during TRUS guided PBx. The pain in TRUS guided PBx should be 
controlled with an optimum dose of prilocaine as 0.1 mL per one mL of 
prostatic tissue.
Keywords: Pain, prilocaine, prostate, periprostatic nerve block, transrectal 
ultrasound
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Introduction
Prostate cancer (PCa) is one of the most encountered cancers 
in men in worldwide (1). The transrectal ultrasound (TRUS) 
guided biopsy of prostate (PBx) is the gold standard method for 
the diagnosis of PCa (2). The pain and discomfort in patients 
under this procedure was reported by several studies (3,4).
Different local anesthetic techniques for TRUS guided PBx 
procedure was described due to the pain and discomfort of the 
patients (5,6,7,8,910). Intrarectal lubricant agents, periprostatic 
nerve blocks (PPNB), intraprostatic anesthesia, caudal or 
pudendal nerve blocks are some of the techniques described 
(11). Although it depends on the patient’s characteristics and 
the urologist’s experience, PPNB is the most effective and 
commonly used method in TRUS guided PBx (12). Although 
several researches were performed for various types and 
amounts of local anesthetic agents in PPNB (5,6,7,8,9,10), 
the optimum type and doses of local anesthetic agent is still 
controversial. 
There are some potential complications of PPNB during PBx. 
The local anesthetic agents have some side effects according 
to infiltration to circulation during PPNB. Nausea, anxiety and 
arrhythmias are some of these complications (11). Though, the 
needle punctures for injection and injected fluid have potential 
risks for bacterial contamination and urinary tract infection 
(11). Some authors have reported that the risk of sepsis did not 
increase with PPNB (13). The injection of local anesthetic agent 
is a painful procedure for the patient (14). Tüfek et al. (15) 
reported that the administration of low volume local anesthetic 
agent decreased the pain during both instillation of local 
anesthetic agent and biopsy, while there was no complication 
related to local anesthetic absorption and the procedure. 
The reduction of pain during TRUS guided PBx with the lowest 
complication risk of PPNB is important for urologists. In the 
present study, we aimed to investigate the optimum dose of 
prilocaine in PPNB during TRUS guided PBx.
Materials and Methods
We retrospectively evaluated the medical records of patients 
with TRUS guided PBx due to elevated serum prostate specific 
antigen (PSA) levels and/or presence of abnormalities in digital 
rectal examination between years 2011 and 2013 in our center. 
This study was approved by our University Institutional Review 
Board (Project No: KA 13/40).
The inclusion criteria of patients in this study were;
• Patients with the first TRUS guided PBx due to elevated serum 
PSA level and/or presence of abnormalities in digital rectal 
examination.
• Patients with 12 core TRUS guided PBx.
• The administration of 5 mL prilocaine as the only local 
anesthetic method during TRUS guided PBx (this method is 
routinely used in our clinic).
On the other hand, the exclusion criteria of patients were 
the presence of bleeding diathesis, urinary tract infection, 
anticoagulant therapy, history of allergy to local anesthetic 
agents, re-biopsy, different doses or types of local anesthetic 
agents as lidocaine or bupivacaine and additional local anesthesia 
during PBx. We retrospectively evaluated the medical records of 
165 patients and according to inclusion and exclusion criteria, 
83 patients were included in the study. Antibiotic prophylaxis 
with 500 mg ciprofloxacin were initiated the night before the 
PBx and continued twice daily for three days after the procedure 
in all patients. None of the patients was administrated fleet 
enema or oral analgesics before the procedure. 
The Technique of Periprostatic Nerve Blocks During Transrectal 
Ultrasound Guided Prostate Biopsy and Evaluation of Pain
All procedures were performed by the same urologists (M.K., 
U.G.) in an outpatient setting. The patient was placed in 
left lateral decubitus position in all ultrasound evolutions, 
local anesthesia administration and PBx sections. A Logiq C2 
ultrasound device with a transrectal probe (GE Healthcare, 
Milwaukee, Wisconsin, USA) was used to evaluate the prostate 
and the local anesthetic agent was injected with a 22 gauge, 
20 cm Chiba aspiration biopsy needle (Geotek Medical 
Cooporation, Ankara, Turkey) in all patients. Five mL 2% 
prilocaine (2.5 mL to each side) was injected just lateral to 
the junction between the prostate base and seminal vesicle on 
each side for PPNB. The prostate was examined in transverse 
and sagittal planes after prilocaine infiltration. Prostatic sizes 
were evaluated separately as Size 1 (anterior-posterior on the 
axial plane), Size 2 (transversal), and Size 3 (cranial-caudal on 
the sagittal plane) in all patients. The ellipsoid formula (Size 
1xSize 2xSize 3x0.52) was used in the calculation of prostate 
volume. Five minutes after prilocaine injection, the PBx was 
performed in transverse plane using a 12 cores technique 
(conventional sextant biopsies+6 laterally targeted biopsies in 
apex, midzone and base of prostate bilaterally) with 18 gauge, 
25 cm maxicore automatic biopsy gun needle using a biopsy 
gun (Geotek Medical Cooporation, Ankara, Turkey). Following 
the procedure, all patients were evaluated for the level of their 
pain during the biopsies with a visual analog scale (VAS) from 0 
(no pain) to 10 (worst pain) points.
Although all patients were injected 5 mL 2% prilocaine in 
PPNB, the dosage of 2% prilocaine per 1 mL prostate volume 
was calculated for each patient (5 mL 2% prilocaine/prostate 
volume of patient). We evaluated the correlation between VAS 
of patients during PBx and patient’s characteristics, prostatic 
volumes, the prostatic sizes and the dosage of 2% prilocaine per 
1 mL prostate. Also we evaluated the VAS-2% prilocaine dose 
response graphic.
Statistical Analysis
The data were presented as mean ± standard deviation. SPSS 
16.0 for Windows (SPSS Inc., Chicago, Illinois, USA) software 
was used for statistical analysis. The power analysis of the 
study was calculated by a statistician before the evaluation of 
patients’ medical records. It was found that a case volume with 
83 patients had a 85% power analysis. The mean values of 
patients data was evaluated with descriptive statistical tests. The 
Spearman’s correlation test was used to evaluate the correlation 
between VAS and 2% prilocaine dosage, prostate sizes and 
prostate volume. We also used the cubic regression test for 
the relationship between VAS and 2% prilocaine dosages. The 
values of p<0.05 were considered as statistically significant.
Results
The medical records of the patients were retrospectively 
evaluated. The characteristics of patients are presented in Table 
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1. The pathological findings of patients in PBx were benign 
prostatic hyperplasia in 59 (71.1%) patients, PCa in 18 (21.7%) 
patients, high grade prostatic intraepithelial neoplasia in one 
(1.2%) patient and atypical small acinar proliferation in 5 (6%) 
patients. According to these results, the main pathological 
diagnosis was benign prostatic hyperplasia in our patients. 
PCa was diagnosed in 18 (21.7%) patients. The complications 
of procedure were observed only in 3 (3.6%) patients. One 
(1.2%) patient with fever and urinary tract infection was 
hospitalized one day after the procedure. One (1.2%) patient 
had a vasovagal syncope and another (1.2%) had transient 
arrhythmia during the procedure. These two biopsies in these 
patients were completed after the conservative therapy. 
We evaluated the correlation between the VAS during PBx 
and other variables as prilocaine dosage per 1 mL prostatic 
tissue and prostatic sizes (Table 2). According to these results, 
VAS of the patients were significantly positive moderate 
correlated with prostatic volume, Size 1 and 3. on the 
other hand, there was a significantly negative moderate 
correlation between VAS and prilocaine dose per 1 mL prostate 
(r=-0.402, p<0.01). 
Our results showed that the most powerful correlation was between 
VAS of the patients and prilocaine dosage per 1 mL prostatic tissue. 
The graphic of the relationship between VAS and prilocaine dosage 
is presented in Figure 1. The formula of the graphic was found to be 
below according to cubic regression test. The dose of 0.1 mL prilocaine 
infiltration per 1 mL prostatic tissue in PPNB was the maximum dose 
that caused a mild and under annoying pain (VAS<2) in patients 
with TRUS guided 12 core PBx according to this formula 
(Figure 1). 
The formula of VAS-Prilocaine dosage curve: VAS=4.545-
(36.847xdosage)+(122.14xdosage2)-(139.111xdosage3)
Discussion
TRUS guided PBx is the main method in the diagnosis of PCa 
(2). A significant pain was reported by investigators in 30% of 
the patients (3,4). Pain and discomfort during PBx depend on 
neuroanatomy of prostate and anal canal. Prostate parenchyma 
and prostate capsule are more sensitive to pain in comparison 
with rectal mucosa. The perforation of prostate capsule with 
biopsy needle mainly generates the pain that is transmitted 
through the neurovascular bundles. The nerves with sensorial 
innervations of prostate capsule and stroma pass through 
the posterolateral border of the prostate capsule at prostatic 
base (11,16,17,18). Local anesthesia is widely used to reduce 
the pain and discomfort of patients during TRUS guided PBx 
(11,19). 
There are various types of local anesthesia during PBx such as 
intrarectal local anesthetic gel, PPNB, intraprostatic anesthesia, 
pelvic plexus blockade (11,19). The usage of PPNB in the control 
of pain during PBx was first described by Nash et al. (16). PPNB is 
the infiltration of local anesthetic agent around the neurovascular 
bundle of prostate. Several meta-analyses have reported that 
PPNB is the best method to control the pain during TRUS guided 
PBx (11,19). Various anesthetic agents as lidocaine, bupivacaine 
and mepivacaine have been used in PPNB. The most frequently 
used agent is lidocain with long duration of action and low 
incidence of side effects (11). Although Tiong et al. (19) reported 
that the complications according to biopsy procedure or local 
anesthetic agents did not increase in patients with PPNB in their 
meta-analysis, it is well known that the local anesthetic agents 
have several side effects including arrhythmias, hypotension and 
anxiety (11). Though it was reported that the incidence of fever, 
urinary tract infection and hospitalization after TRUS guided 
PBx are higher in patients with PPNB, it was known that these 
complications were also common in patients without PPNB (11). 
On the other hand, Gan et al. (13) reported that PPNB during 
TRUS guided PBx did not increase the risk of sepsis. Song et 
al. (20) also reported the incidence of vasovagal syncope was 
1%. Turgut et al. (21) reported that systemic lidocaine toxicity 
had been seen in 2% of patients with PPNB. In this study, we 
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Figure 1. The graphic of visual analog scale scores and prilocaine 
dosage according to cubic regression test
VAS: Visual analog scale
Table 2. The Spearman’s Correlation tables according to visual 
analog scale score
Parameters r value p value
Age -0.019 0.86
PSA +0.187 0.09
Prilocaine dosage -0.402 <0.01
Size 1 +0.389 <0.01
Size 2 +0.232 0.03
Size 3 +0.328 <0.01
Prostate volume +0.303 <0.01
PSA: Prostate specific antigen 
Table 1. The demographic characteristics and prostate sizes of 
patients
Parameters Mean ± SD
Age (year) 64.8±7.9
PSA (ng/mL) 15.1±18.1
Size 1 (mm) 41.5±10.5
Size 2 (mm) 57±7.9
Size 3 (mm) 53.6±10.3
Prostate volume (ml) 72.2±47.1
VAS 2.3±1.9
PSA: Prostate specific antigen, VAS: Visual analog scale, SD: Standard deviation
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observed the vasovagal syncope in one (1.2%) patient and 
transient arrhythmia in one (1.2%) patient. It was needed to 
hospitalize one (1.2%) patient due to fever and urinary infection 
in our study. 
There are several studies with different type, concentration or 
dosage of local anesthetic agents in PPNB during TRUS guided 
PBx (10,15,22,23,24,25). The technique of PPNB was also 
different in recent studies (8,22,23,26). The most frequently 
used agent in PPNB was lidocaine with 1-2% concentrations 
(11,19,22,23). The widely used applications of lidocaine were 5 
or 10 mL in several studies (6,8,26). Although it was reported 
that patients had lower pain during PBx with high volume 
of local anesthetics in PPNB, the high concentration of local 
anesthetics in low volumes had better control of pain in PBx 
(9,15,27). Bupivacaine, ropivacaine and prilocaine are the less 
frequently used agents in PPNB (5,10). The bilateral angel 
between the prostate base and seminal vesicle is the most 
common injection site in PPNB (11). In this study, 5 mL 2% 
prilocaine (2,5 mL per each side) was used in PPNB and injected 
the local anesthetic to the angel between the prostate base and 
seminal vesicle bilaterally. 
In a recent review, Loeb et al. (28) presented the prostate 
volume as another predictor for pain during PBx. Some 
investigators reported that the prostate volume was not an 
important risk factor for pain associated with PBx (29). Bastide 
et al. (29) evaluated the risk factors of pain during PBx in 
patients without any anesthetic method and reported that the 
only risk factor for pain was the initial localization of PBx. On 
the other hand, Giannarini et al. (6) compared the efficiency of 
combination perianal-intrarectal lidocaine-prilocaine cream and 
PPNB with the two modalities alone during PBx. They reported 
that the combination of both anesthetic methods had better 
pain control during PBx and this effect was higher in patients 
with larger prostate volume. Patients with larger prostate 
volume needed more anesthetics during PBx (6). Additionally, 
Yun et al. (30) showed that patients with prostate volume 
larger than 40 mL had more pain during and after TRUS guided 
PBx in comparison with patients with smaller prostate. Eight 
mL of 1% lidocaine was administered to all patients at both 
basolateral region of prostate for PPNB in their study (30). In 
this study, we did not evaluate the patients by dividing into 
groups according to their prostate volumes. We evaluated the 
relationship between the VAS of patients during PBx and the 
sizes of prostate. Prostate volume and the prostatic sizes were 
positively correlated with VAS of the patients. We found that 
the anatomical structure of prostate had an impact on the 
efficiency of PPNB. Anterior-posterior and cranial-caudal sizes 
of prostate had stronger relationships with VAS in comparison 
of prostate volume. The increased sizes of prostate might affect 
the infiltration anesthesia of periprostatic nerve negatively in 
these patients. It was found that the dosage of prilocaine per 1 
mL prostatic tissue was negatively correlated with VAS and the 
optimum dosage for PBx procedure was 0.1 mL prilocaine per 
1 mL prostatic tissue in PPNB. The VAS of the patients with this 
optimum dosage of prilocaine was under annoying pain (VAS 
<2) according to dose-response curve in our study.
To thwe best of our knowledge, this study is the first one to 
calculate the optimum dosage of local anesthetic agent in PPNB 
according to prostatic volume. We found that 0.1 mL prilocaine 
per 1 mL prostatic tissue in PPNB made the procedure less 
painful for patients with 12 cores PBx. The optimum dosage for 
anesthetic agents is important due to avoid the possible side 
effects of agents and puncture of needle. This study has some 
limitations according to its retrospectively designed nature. 
The main limitation of the study was the absence of the VAS 
of patients during PPNB and post PBx. We only evaluated the 
VAS of patients during PBx. Another limitation was the usage 
of single kind of local anesthetic agent prilocaine in our study.
The present study showed the relationship between the 
prostatic volume and the pain during PBx. The importance of 
this study was the calculation of an optimum dosage of local 
anesthetic agent in PPNB according to the prostatic volume. 
We found that the pain during PBx was negatively correlated 
with the dosage of prilocaine per 1 mL prostatic tissue and 
positively correlated with prostatic sizes (especially anterior-
posterior and cranial-caudal sizes) and volume. The changes in 
anatomical structure of prostate have an impact on infiltration 
anesthesia of local anesthetic agents in PPNB. The optimum 
dosage of prilocaine was 0.1 mL prilocaine per 1 mL prostatic 
tissue in PPNB for patients with 12 cores PBx. Unfortunately; 
prospectively designed studies with high caseloads are needed 
to find the optimum dosages for all local anesthetic agents in 
PPNB during TRUS guided PBx.
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